Market Overview

PTC Therapeutics Shares Spike After FDA Approves Drug For Younger Patients

PTC Therapeutics Shares Spike After FDA Approves Drug For Younger Patients

PTC Therapeutics, Inc. (NASDAQ: PTCT) announced Friday that the Food and Drug Administration approved a label expansion for the drug Emflaza to include younger patients with Duchenne muscular dystrophy who are between 2 and 5 years old. 

PTC Therapeutics shares were trading higher by 2.73 percent to $41.40 at the time of publication Friday. 

Duchenne muscular dystrophy is a rare childhood genetic disorder that causes progressive, irreversible muscle deterioration and weakness.  

Duchenne is a severe type of muscular dystrophy, and symptoms of muscle weakness usually begin around the age of 4 in boys and worsen quickly; females with a single copy of the defective gene may show mild symptoms.

Emflaza was first approved by the FDA in February 2017 for the treatment of Duchenne in patients 5 and older. 

"We are excited to be able to bring Emflaza to younger boys living with Duchenne muscular dystrophy," PTC Therapeutics CEO Stuart Peltz said in a statement. 

"The standard of care is to start Emflaza at the time of diagnosis. We believe that treating patients as young as possible, when they still have a substantial amount of muscle, will have the greatest benefit for patients that are two years and older." 

Related links:

US Adds 75,000 Jobs In May, Far Below Estimates

A Peek Into The Markets: US Stock Futures Surge; All Eyes On Jobs Report

Posted-In: Duchenne Muscular Dystrophy EmflazaBiotech News FDA General Best of Benzinga


Related Articles (PTCT)

View Comments and Join the Discussion!
Fastest Market News Application
You'll Hear It First On Pro
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Trading Daily
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at

KeyBanc Not Worried About DocuSign Billing 'Hiccup,' Guidance

Mid-Afternoon Market Update: Beyond Meat Jumps After Strong Q1 Results; DocuSign Shares Slide